Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 250

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 250
---
 active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic
indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at
the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example,
the product is sufficiently profitable not to justify market exclusivity.

PRC Regulation

Although, as noted elsewhere
in this proxy statement/prospectus that we do not currently have operations in the PRC, as also noted, the PRC government may intervene
or influence our operations in Hong Kong at any time and with no advance notice. Therefore, we include below a brief summary of material
regulations that may impact our business or operations, including if we seek IP approval in the PRC. As of the date hereof, we do
have an exclusive license of certain PRC patents directed to certain drug candidates.

Permission Required from the PRC Authorities

As of the date hereof, we are
not required to obtain approvals from the PRC authorities to operate our business or list on the U.S. exchanges and offer or continue
to offer securities; specifically, we are currently not required to obtain any permission or approval from the CSRC, the CAC or any other
PRC governmental authority to operate our business or to list our securities on a U.S. securities exchange or issue securities to
foreign investors. We do not believe that the laws and regulations of mainland China currently have any material impact on our business,
financial condition or results of operations and we are currently not subject to the PRC government’s direct influence or discretion
over the manner in which we conduct our business activities outside of the mainland China, however that can change at any time without
any advance notice to us, which could adversely impact our business and operations.

<div align='center'>138</div>

Nevertheless, we are aware
that recently, the PRC government initiated a series of regulatory actions and statements to regulate business operations in certain areas
in mainland China with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision
over mainland Chinese companies listed overseas using a VIE structure, adopting new measures to extend the scope of cybersecurity reviews,
and expanding the efforts in anti-monopoly enforcement. Since these statements and regulatory actions are new, it is highly uncertain
how soon the legislative or administrative regulation making bodies will respond and what existing or new laws or regulations